abil
detect
nucleic
acid
still
major
impact
diagnost
clinic
virolog
quantit
qualit
techniqu
whether
signal
target
amplif
base
system
current
use
routin
virolog
laboratori
technolog
improv
autom
sampl
isol
real
time
amplif
technolog
given
abil
develop
introduc
system
virus
clinic
interest
obtain
clinic
relev
inform
need
optim
antivir
treatment
option
polymeras
chain
reaction
pcr
nucleic
acid
sequencebas
amplif
nasba
current
use
togeth
real
time
detect
gener
result
short
turnaround
time
determin
whether
variant
relev
antivir
resist
present
new
technolog
enabl
introduct
individu
patient
diseas
manag
concept
within
clinic
set
introduc
eg
quantit
detect
epstein
viru
ebv
tdell
deplet
allogen
stem
cell
transplant
patient
enabl
us
develop
model
preemptiv
anti
bcell
immunotherapi
ebv
reactiv
therebi
effect
reduc
incid
ebvlymphoprolif
diseas
viru
relat
mortal
furthermor
addit
clinic
relev
virus
easili
detect
simultan
also
becom
feasibl
introduc
molecular
test
virus
easili
detect
use
classic
virolog
method
like
cultur
techniqu
antigen
detect
prospect
studi
need
evalu
clinic
import
addit
posit
sampl
detect
howev
made
clear
complet
exchang
technolog
unlik
occur
complementari
technolog
stay
oper
enabl
discoveri
new
virus
implement
molecular
diagnost
technolog
furthermor
warrant
use
introduct
standard
materi
well
particip
intern
qualiti
control
program
final
use
intern
control
throughout
whole
procedur
ensur
accuraci
result
gener
also
necessari
enabl
precis
quantif
result
determin
detect
threshold
accur
sinc
mani
target
clinic
implic
laboratori
might
prefer
use
univers
intern
control
inhous
develop
assay
introduc
clinic
virolog
sever
achiev
made
last
decad
enabl
sensit
detect
character
viral
nucleic
acid
amplif
technolog
like
polymeras
chain
reaction
pcr
nucleic
acid
sequencebas
amplif
nasba
make
amplif
principl
target
interest
possibl
furthermor
technolog
improv
sequenc
detect
system
enabl
fulli
character
viru
determin
instanc
subtyp
genotyp
variant
mutant
genotyp
resist
pattern
implement
nucleic
acid
technolog
routin
diagnost
made
great
step
forward
introduct
real
time
technolog
make
detect
amplifi
product
rel
easi
niester
mackay
et
al
furthermor
technolog
abl
quantifi
target
nucleic
acid
singl
sampl
larger
dynam
rang
quantit
technolog
although
qualit
detect
cours
also
possibl
sinc
amplif
detect
current
perform
automat
labor
intens
critic
step
remain
effici
extract
nucleic
acid
differ
clinic
sampl
second
achiev
clinic
virolog
increas
number
antivir
strategi
possibl
human
immunodefici
viru
type
also
virus
like
ebv
enterovirus
new
antivir
strategi
howev
use
success
combin
optim
diagnost
strategi
turnaround
time
gener
result
must
rel
short
furthermor
base
establish
risk
factor
strategi
employ
diseas
manag
concept
integr
approach
anticip
optim
clinic
econom
outcom
howev
number
problem
need
solv
molecular
diagnost
realli
implement
routin
tabl
first
well
recogn
clinic
laboratori
commerci
standard
assay
avail
limit
number
viral
target
unlik
number
target
virus
increas
rapidli
near
futur
howev
emphas
larg
grow
list
virus
implement
use
nucleic
acid
technolog
advantag
tabl
tent
list
call
commerci
interest
virus
versu
viral
target
limit
commerci
interest
given
second
bottleneck
easi
reproduc
isol
nucleic
acid
rna
dna
sever
clinic
specimen
mani
open
system
current
avail
howev
need
fulli
autom
system
high
reliabl
essenti
complet
implement
nucleic
acid
detect
daytoday
clinic
virolog
set
furthermor
enabl
laboratori
gener
result
short
turnaround
time
essenti
patient
diseas
manag
must
howev
mention
limit
inform
avail
indic
function
avail
instrument
diagnost
set
third
bottleneck
deal
standard
qualiti
control
program
known
sinc
earli
one
greatest
hurdl
overcom
molecular
technolog
falseposit
due
contamin
falseneg
due
great
differ
sensit
case
homebrew
assay
quint
et
al
schuurman
et
al
zaaijer
et
al
furthermor
differ
detect
genotyp
equal
eg
hepat
c
viru
hcv
amplif
effici
also
report
damen
et
al
zaaijer
et
al
program
within
europ
initi
inde
shown
need
obtain
standard
materi
need
particip
program
valentinethon
et
al
van
vliet
et
al
successor
one
initi
call
qualiti
control
molecular
diagnost
qcmd
http
wwwqcmdorg
endors
european
societi
clinic
virolog
escv
european
societi
microbiolog
infecti
diseas
escmid
start
provid
qualiti
control
program
increas
number
viral
target
whether
commerci
interest
asid
need
well
defin
qualiti
control
program
still
lack
standard
quantit
assay
mainli
due
fact
standard
limit
select
number
blood
born
virus
like
hepat
b
viru
hbv
hcv
intern
accept
world
health
organ
standard
made
avail
saldanha
et
al
saldanha
et
al
standard
unfortun
singl
viral
genotyp
subtyp
case
focus
specif
blood
bank
screen
routin
virolog
diagnost
lack
focu
standard
one
hurdl
need
taken
inhous
develop
assay
noncommerci
interest
viral
target
introduc
magnapur
lc
system
roch
appli
scienc
penzberg
germani
laboratori
open
extract
system
initi
extract
rna
dna
serum
plasma
combin
real
time
detect
whether
taqman
technolog
nasba
amplif
enabl
us
automat
extract
subsequ
detect
rna
dna
larg
dynam
rang
singl
clinic
sampl
monitor
extract
process
loss
inhibit
introduc
use
univers
intern
viral
control
consist
complet
dna
viru
nonhuman
seal
herp
viru
type
real
time
quantit
taqman
assay
develop
seal
herpesviru
grown
rel
easili
cell
cultur
meanwhil
also
introduc
univers
rna
viru
intern
control
phocin
distemp
viru
assumpt
viru
use
univers
control
behav
similar
extract
procedur
target
viru
interest
contrast
use
eg
plasmid
intern
control
low
fix
amount
viru
equal
amount
give
ct
valu
real
time
assay
approxim
depend
lot
number
use
ad
clinic
sampl
case
mostli
serum
plasma
extract
procedur
start
viru
coextract
subsequ
amplifi
quantit
manner
separ
tube
methodolog
enabl
monitor
combin
effect
extract
loss
sampl
amplif
inhibit
enabl
confid
quantit
result
gener
viral
target
interest
also
neg
result
clinic
sampl
target
detect
therefor
gener
high
confid
data
intern
control
routin
import
spreadsheet
program
defin
threshold
approv
disapprov
final
result
typic
exampl
shown
fig
current
multiplex
clinic
sampl
intern
control
develop
strategi
enabl
us
monitor
everi
new
strategi
new
equip
technolog
extract
rapidli
enabl
us
check
whether
differ
lot
number
reagent
behav
ident
cours
assumpt
amplif
effici
univers
intern
control
within
rang
target
interest
final
extern
standard
also
less
ident
sampl
interest
similar
amplif
effici
clinic
sampl
matrix
extern
control
extract
extract
similar
compar
sampl
interest
impli
clone
materi
extern
control
might
problemat
fig
data
cycl
threshold
ct
valu
amplif
plot
seal
herp
viru
type
ad
fix
concentr
approxim
copi
per
ml
clinic
result
singl
experi
shown
import
spreadsheet
program
viru
coextract
use
magnapur
lc
isol
station
quantifi
sequenc
detect
system
use
taqman
univers
reaction
mixtur
appli
biosystem
nieuwerkerk
aan
de
ijssel
netherland
primer
probe
sequenc
forward
primer
gggcgaatcacagattgaatc
revers
primer
gcggttccaaacgtaccaa
probe
label
tet
tttttatgtgtccgccaccatctggatc
amplif
product
bp
within
gb
gene
gener
averag
ct
valu
averag
sampl
analyz
lot
number
sd
sampl
ct
valu
intern
control
averag
plu
sd
repeat
one
run
see
arrow
problem
standard
intern
standard
alreadi
address
conclus
absolut
quantif
hard
achiev
definit
viral
target
would
classifi
commerci
interest
moment
intern
collabor
diagnost
laboratori
take
lead
enabl
tackl
problem
cours
exclud
use
real
time
technolog
quantifi
viral
target
sinc
shown
give
invalu
inform
virus
host
interact
recent
develop
real
time
technolog
like
taqman
hydrolysi
probe
hybrid
probe
molecular
beacon
detect
amplif
product
gener
pcr
nasba
technolog
quantif
rna
dna
clinic
sampl
much
easier
also
avail
readytogo
reagent
rt
pcr
nasba
step
forward
numer
exampl
detect
quantif
viral
target
publish
alreadi
list
grow
rapidli
niester
conclus
whole
process
isol
detect
autom
howev
target
optim
strategi
still
need
establish
determin
threshold
valu
clinic
import
detect
level
need
reach
assay
involv
develop
preemptiv
strategi
reduc
incid
epstein
viru
ebv
reactiv
develop
ebv
relat
lymphoma
known
posttranspl
lymphoprolif
diseas
ptld
allogen
tcell
deplet
stem
cell
transplant
patient
taqman
base
assay
gene
encod
bnrf
protein
develop
use
investig
incid
ebv
reactiv
develop
ebv
relat
ptld
van
esser
et
al
van
esser
et
al
b
moreov
assay
perform
frequent
fig
preemptiv
antib
cell
immunotherapi
ebv
monitor
patient
risk
ebv
relat
posttranspl
lymphoprolif
diseas
ebv
dna
load
measur
regular
basi
level
copi
per
ml
patient
recal
hospit
preemptiv
therapi
rituximab
tm
anticd
therapi
initi
monitor
perform
almost
daili
basi
five
time
week
ebv
dna
level
twice
limit
detect
copi
per
ml
signal
decreas
rapidli
increas
observ
second
infus
rituximab
tm
infus
donor
lymphocyt
dli
given
see
data
repres
thick
line
initi
preemptiv
therapi
repres
day
line
repres
individu
patient
three
current
five
time
week
enabl
determin
kinet
ebv
replic
patient
popul
sever
interest
conclus
could
drawn
one
stepwis
increas
ebv
dna
measur
plasma
yield
hazard
ratio
confid
interv
develop
ptld
patient
receiv
tcell
deplet
graft
p
furthermor
shown
patient
receiv
antithymocyt
globulin
atg
part
condit
regimen
belong
popul
highest
risk
cell
deplet
question
rais
viral
load
one
interven
preemptiv
antivir
strategi
ie
precis
identifi
patient
risk
threshold
copi
per
ml
plasma
chosen
start
treatment
rituximab
monoclon
antibodi
direct
receptor
bindingsit
ebv
although
result
overtreat
patient
ebv
reactiv
like
would
develop
ebvptld
reduct
ebvptld
incid
complet
abrog
ptldmortal
month
observ
van
esser
et
al
exampl
kinet
pattern
observ
ebv
dna
measur
plasma
shown
fig
observ
ebv
dna
viral
load
increas
rapidli
make
necessari
perform
real
time
test
regular
basi
monitor
patient
risk
follow
initi
treatment
frequent
thu
necessari
advantag
isol
nucleic
acid
use
gener
method
also
enabl
detect
sever
clinic
import
virus
simultan
definit
grow
popul
immunocompromis
patient
strategi
seem
fruit
fig
show
exampl
simultan
detect
herpesvirus
ebv
human
cytomegaloviru
cmv
bone
marrow
transplant
patient
abl
detect
quantifi
princip
viru
interest
question
remain
whether
character
isol
detect
viru
inform
patient
manag
shown
blood
born
virus
character
viru
becom
less
routin
practic
clinic
virolog
genotyp
resist
pattern
usual
obtain
sequenc
revers
transcriptas
proteas
gene
gener
lot
inform
enabl
optim
antiretro
fig
simultan
detect
ebv
human
cytomegaloviru
cmv
bone
marrow
transplant
patient
use
gener
isol
techniqu
viral
nucleic
acid
isol
magnapur
lc
isol
station
edta
plasma
sampl
detect
ebv
cmv
perform
use
real
time
taqman
detect
sequenc
detect
system
ensur
accur
result
fix
amount
seal
herp
viru
type
ad
sampl
extract
initi
extern
standard
electron
microscop
count
ebv
cmv
standard
advanc
biotechnolog
inc
columbia
usa
use
viral
therapi
done
mostli
combin
gener
quantit
rna
data
hepat
c
viru
genotyp
import
combin
viral
load
determin
durat
therapi
use
interferon
ribavirin
easl
number
technolog
achiev
sequenc
princip
ultim
way
character
disadvantag
antivir
treatment
mixtur
wild
type
variant
viru
coexist
observ
sequenc
suitabl
detect
minor
popul
variant
virus
schuurman
et
al
technolog
revers
hybrid
stuyver
et
al
stuyver
et
al
pa
et
al
restrict
fragment
length
polymorph
rflp
analysi
allen
et
al
niester
et
al
might
suitabl
clear
success
sequenc
chang
known
specif
gene
viral
load
measur
support
search
new
variant
recent
identifi
new
variant
socal
ymdd
motif
polymeras
gene
hbv
methionin
replac
serin
develop
new
rflp
analysi
could
determin
dynam
wild
type
variant
sequenc
present
antivir
therapi
fig
estim
approxim
million
hbv
chronic
carrier
worldwid
measur
hbv
dna
serum
becom
import
tool
identifi
individu
high
viral
replic
might
benefit
antivir
therapi
monitor
patient
therapi
predict
whether
antivir
therapi
success
dynam
rang
hbv
detect
patient
ten
log
immedi
impli
current
commerci
avail
technolog
unabl
fig
analysi
patient
chronic
infect
hepat
b
viru
hbv
antivir
therapi
lamivudin
close
monitor
use
alanin
aminotransferas
alt
hbv
dna
valu
perform
dna
valu
increas
antivir
therapi
sequenc
analysi
identifi
new
variant
ysdd
restrict
fragment
length
polymorph
analysi
develop
enabl
detect
wild
type
bp
fragment
variant
viru
bp
fragment
period
interferonalpha
ad
lamivudin
treatment
howev
alt
flare
observ
addit
interferonalpha
stop
end
treatment
wild
type
variant
viru
detect
simultan
detail
see
niester
et
al
quantifi
without
dilut
concentr
sampl
real
time
amplif
thu
definit
technolog
use
pa
et
al
introduct
new
antivir
drug
like
lamivudin
thiacytidin
close
monitor
patient
becom
increasingli
import
due
occurr
viral
resist
strain
presenc
flare
withdraw
antivir
therapi
honkoop
et
al
honkoop
et
al
implement
molecular
technolog
clinic
virolog
result
improv
diagnost
number
virus
use
quantit
detect
nucleic
acid
monitor
antivir
therapi
especi
hbv
hcv
also
develop
amplif
assay
almost
everi
human
viru
also
virus
cultur
rel
easili
like
eg
hsv
type
espi
et
al
new
molecular
technolog
sever
advantag
definit
set
routin
viru
cultur
avail
howev
also
note
improv
sensit
observ
instanc
implement
molecular
diagnost
routin
clinic
diagnost
virolog
proceed
could
ultim
replac
reduc
viru
cultur
techniqu
implement
autom
extract
detect
technolog
combin
extens
qualiti
control
program
ultim
convinc
clinician
virologist
molecular
diagnost
strong
cornerston
clinic
virolog
final
critic
remark
often
mention
posit
result
clinic
signific
counterpart
good
clinic
epidemiolog
inform
combin
quantit
inform
one
virus
present
howev
abil
exclud
viral
infect
advantag
unnecessari
therapeut
option
avoid
inevit
reduc
overal
cost
patient
care
need
financi
figur
prove
thu
improv
accuraci
sensit
combin
rapid
turn
around
time
molecular
technolog
import
clinic
patient
care
provid
inform
best
therapeut
option
cours
still
need
viru
cultur
otherwis
unabl
identifi
new
virus
circul
like
human
metapneumoviru
van
den
hoogen
et
al
clear
larg
transit
viru
cultur
molecular
diagnost
hand
avail
open
technolog
enabl
routin
isol
nucleic
acid
increas
number
clinic
materi
also
due
implement
real
time
detect
system
whole
process
perform
semiautomat
quantit
detect
viral
rna
dna
target
furthermor
risk
contamin
minim
turnaround
time
gener
result
minim
handl
personnel
whether
posit
neg
becom
shorter
result
gener
easili
within
work
day
although
often
necessari
expect
near
futur
reduc
hour
molecular
technolog
becom
matur
part
routin
clinic
virolog
also
homebrew
assay
becom
matur
sinc
standard
reagent
improv
qualiti
control
program
enhanc
laboratori
perform
importantli
standard
reagent
get
cheaper
time
make
discuss
high
cost
rather
obsolet
one
greatest
advantag
howev
abil
detect
posit
target
sequenc
clinic
sampl
give
us
insight
relat
viru
host
importantli
patient
risk
treat
specif
molecular
test
rather
success
area
convent
virolog
techniqu
exist
could
improv
current
molecular
test
also
avail
target
convent
technolog
avail
logist
within
laboratori
price
assay
well
clinic
benefit
new
criteria
make
technolog
improv
realli
part
new
era
diagnost
set
